Follicum
After a more thorough evaluation of FOL-005’s data from a phase 2 clinical trial, new management at Follicum believes that its drug candidate has a place in the treatment landscape for androgenic alopecia and they want to explain why. FOL-005 Phase 2 Results Revisited In February 2022, Follicum AB was acquired by Coegin Pharma, a…
On May 6, 2021 the Swedish biotech company Follicum announced results from its pivotal phase 2 trial which represented the first time its candidate peptide FOL-005 was tested topically to treat male pattern baldness. FOL-005 Grew Hair, But Not Quite Enough To keep things succinct, FOL-005 did not reach its goal in the phase 2…
Phase 2 Trial Of Topical FOL-005 Has Resumed- Update 6/9/20 After a nearly 3 month intermission due to coronavirus restraints, Follicum is now able to continue recruitment for its phase 2 trial of a topical FOL-005 formulation. In addition to restarting the trial, Follicum has enlisted a third study center, CentroDerm of Wuppertal, Germany, to…
Swedish company Follicum has announced new information regarding their clinical trial schedule and product development. The last completed milestone we had heard from Follicum was results from their phase 2a clinical trial of FOL-005. During that trial which completed in late 2018, the peptide FOL-005 was injected into the scalps of 60 participants three times…
CEO of Follicum, Jan Alenfall, recently presented his company at the BioStock meeting which took place on April 29, 2019 in Stockholm, Sweden. The presentation details Follicum’s successes and plans for its diabetes and hair growth programs. Follicum’s hair growth program is composed of its peptide drug called FOL-005.The section discussing the hair growth program…
Swedish biotechnology company Follicum announced yesterday it has filed a new patent application for its topical formulation of FOL-005. The news came via a press release on Follicum’s website. The press release mentions that: “With the new formulation, it will be possible to study several different doses and increase the dosage frequency in a simple…
On February 4, 2019 Follicum announced via press release they have completed a preclinical trial using a new cream-like topical formulation of their peptide FOL-005. In the trial, Follicum measured the effects of their topical FOL-005 against industry standard hair-growth drug minoxidil. The trial was done on mice and took about four weeks to complete.…
(Updated Below) As the company promised to do earlier this month, Follicum has released data from its phase 2a study which concluded in August earlier this year. This was the first trial Follicum conducted using FOL-005, a modified peptide, on human scalps. In this recent scalp study, five doses (including placebo) were evaluated where patients…
According to its latest news update, Follicum will present top-line data from its recent phase 2a trial by the end of the month. The phase 2a trial for Follicum’s hair growth candidate FOL-005 was completed at sites in Hamburg and Berlin, Germany at the end of August this year. The study comprised 60 patients (assumed…
Another important milestone has been achieved by the Swedish biotech company Follicum. Today, Follicum announced that all patients participating in their phase 2a clinical trial have completed treatment. The phase 2a trial took place at centers in Berlin and Hamburg, Germany and was carried out over the past 3 months. 60 subjects participated and received…